Turn Therapeutics (NASDAQ:TTRX) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Turn Therapeutics (NASDAQ:TTRX) from a hold rating to a sell rating in a research note released on Sunday morning,Wall Street Zen reports.

Other analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. WBB Securities reiterated a “sell” rating and issued a $10.00 price objective on shares of Turn Therapeutics in a research note on Monday, September 14th. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. Finally, Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Turn Therapeutics Trading Down 2.5%

Shares of Turn Therapeutics stock opened at $10.47 on Friday. The stock has a 50 day moving average price of $11.63 and a two-hundred day moving average price of $8.03. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $16.45. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Sell-side analysts forecast that Turn Therapeutics will post -0.40 earnings per share for the current year.

Institutional Investors Weigh In On Turn Therapeutics

Several large investors have recently made changes to their positions in TTRX. SteelPeak Wealth LLC boosted its holdings in shares of Turn Therapeutics by 0.7% in the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock worth $3,616,000 after buying an additional 1,819 shares during the last quarter. Ieq Capital LLC bought a new position in Turn Therapeutics during the second quarter valued at about $1,660,000. BlackRock Inc. purchased a new stake in Turn Therapeutics during the second quarter worth about $282,000. Bridgewater Advisors Inc. purchased a new stake in Turn Therapeutics during the second quarter worth about $242,000. Finally, DDFG Inc increased its holdings in Turn Therapeutics by 34.9% during the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after buying an additional 18,246 shares during the last quarter.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.